Kidney cancer trial: to cut or not to cut after immunotherapy?
NCT ID NCT03977571
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether removing the kidney tumor after starting immunotherapy helps people with advanced kidney cancer live longer. About 400 participants will be randomly assigned to have surgery or not. The goal is to see if delayed surgery improves overall survival compared to no surgery at all.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cytoreductive nephrectomy (surgery to remove part or all of the kidney)
What this could lead to
If successful, this could show that delayed kidney removal after immunotherapy helps people with advanced kidney cancer live longer.
What could go wrong
This is a Phase 2/3 trial, so results are not yet proven. Surgery carries risks like infection or bleeding, and the benefit over no surgery is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Oncology, Aarhus University Hospital
RECRUITINGAarhus, Central Region of Denmark, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of Oncology, Herlev Hospital
RECRUITINGHerlev, 2730, Denmark
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Department of Oncology, Odense University Hospital
RECRUITINGOdense, 5000, Denmark
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Department of Oncology, Stavanger Universitetssykehus
RECRUITINGStavanger, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Department of Oncology, Ålesund Universitetsykehus
RECRUITINGÅlesund, Norway
Contact Email: •••••@•••••
Contact
-
Department of Urology, Haukeland University Hospital
RECRUITINGBergen, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact